MX2021004159A - Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc. - Google Patents
Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc.Info
- Publication number
- MX2021004159A MX2021004159A MX2021004159A MX2021004159A MX2021004159A MX 2021004159 A MX2021004159 A MX 2021004159A MX 2021004159 A MX2021004159 A MX 2021004159A MX 2021004159 A MX2021004159 A MX 2021004159A MX 2021004159 A MX2021004159 A MX 2021004159A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cyclic group
- cns disorders
- neuroactive steroids
- steroids substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745109P | 2018-10-12 | 2018-10-12 | |
| PCT/US2019/055926 WO2020077255A1 (en) | 2018-10-12 | 2019-10-11 | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004159A true MX2021004159A (es) | 2021-09-08 |
Family
ID=68425315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004159A MX2021004159A (es) | 2018-10-12 | 2019-10-11 | Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc. |
| MX2024011494A MX2024011494A (es) | 2018-10-12 | 2021-04-09 | Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011494A MX2024011494A (es) | 2018-10-12 | 2021-04-09 | Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11634453B2 (enExample) |
| EP (2) | EP3864022B1 (enExample) |
| JP (3) | JP7671244B2 (enExample) |
| CN (2) | CN113166193B (enExample) |
| AR (1) | AR116695A1 (enExample) |
| AU (2) | AU2019357040B2 (enExample) |
| BR (1) | BR112021009428A2 (enExample) |
| CA (1) | CA3115805A1 (enExample) |
| DK (1) | DK3864022T3 (enExample) |
| ES (1) | ES2966055T3 (enExample) |
| IL (1) | IL282183A (enExample) |
| MX (2) | MX2021004159A (enExample) |
| TW (2) | TWI886813B (enExample) |
| WO (1) | WO2020077255A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| AU2019357040B2 (en) | 2018-10-12 | 2025-03-27 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DK1038880T3 (da) * | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| BR9509764A (pt) | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
| PT837874E (pt) | 1995-06-06 | 2005-03-31 | Euro Celtique Sa | Esteroides neuroactivos da serie androstano e pregnano |
| UA73736C2 (en) | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| DK2935307T3 (en) | 2012-12-18 | 2018-07-30 | Univ Washington | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| CA3086299A1 (en) | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3728285B1 (en) | 2017-12-22 | 2026-04-08 | Sage Therapeutics, LLC | Compositions and methods for treating cns disorders |
| US12139508B2 (en) | 2018-02-11 | 2024-11-12 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| AU2019357040B2 (en) | 2018-10-12 | 2025-03-27 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders |
| CA3143545A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| BR112021026447A2 (pt) * | 2019-06-27 | 2022-04-12 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios de cns |
| AU2021238346A1 (en) | 2020-03-18 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN115768781A (zh) | 2020-06-24 | 2023-03-07 | 萨奇治疗股份有限公司 | 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物 |
-
2019
- 2019-10-11 AU AU2019357040A patent/AU2019357040B2/en active Active
- 2019-10-11 ES ES19797472T patent/ES2966055T3/es active Active
- 2019-10-11 CN CN201980079330.5A patent/CN113166193B/zh active Active
- 2019-10-11 WO PCT/US2019/055926 patent/WO2020077255A1/en not_active Ceased
- 2019-10-11 EP EP19797472.8A patent/EP3864022B1/en active Active
- 2019-10-11 US US17/284,206 patent/US11634453B2/en active Active
- 2019-10-11 CA CA3115805A patent/CA3115805A1/en active Pending
- 2019-10-11 MX MX2021004159A patent/MX2021004159A/es unknown
- 2019-10-11 EP EP23197779.4A patent/EP4321519B1/en active Active
- 2019-10-11 DK DK19797472.8T patent/DK3864022T3/da active
- 2019-10-11 CN CN202511082220.8A patent/CN121045302A/zh active Pending
- 2019-10-11 AR ARP190102913A patent/AR116695A1/es unknown
- 2019-10-11 BR BR112021009428-8A patent/BR112021009428A2/pt unknown
- 2019-10-11 JP JP2021519712A patent/JP7671244B2/ja active Active
- 2019-10-14 TW TW113106814A patent/TWI886813B/zh active
- 2019-10-14 TW TW108136955A patent/TWI835884B/zh active
-
2021
- 2021-04-08 IL IL282183A patent/IL282183A/en unknown
- 2021-04-09 MX MX2024011494A patent/MX2024011494A/es unknown
-
2023
- 2023-02-21 US US18/171,798 patent/US12686700B2/en active Active
-
2024
- 2024-02-14 JP JP2024020461A patent/JP7899241B2/ja active Active
-
2025
- 2025-01-22 AU AU2025200422A patent/AU2025200422A1/en active Pending
-
2026
- 2026-05-15 JP JP2026082628A patent/JP2026126430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL282183A (en) | 2021-05-31 |
| US20240376144A9 (en) | 2024-11-14 |
| AU2019357040A1 (en) | 2021-05-20 |
| CN113166193B (zh) | 2025-08-19 |
| CA3115805A1 (en) | 2020-04-16 |
| TWI886813B (zh) | 2025-06-11 |
| TW202448479A (zh) | 2024-12-16 |
| JP7899241B2 (ja) | 2026-08-03 |
| ES2966055T3 (es) | 2024-04-18 |
| BR112021009428A2 (pt) | 2021-08-31 |
| EP4321519A2 (en) | 2024-02-14 |
| JP2022504607A (ja) | 2022-01-13 |
| TWI835884B (zh) | 2024-03-21 |
| CN113166193A (zh) | 2021-07-23 |
| CN121045302A (zh) | 2025-12-02 |
| US20210340172A1 (en) | 2021-11-04 |
| EP4321519B1 (en) | 2026-04-08 |
| JP2026126430A (ja) | 2026-08-04 |
| EP3864022B1 (en) | 2023-09-20 |
| JP7671244B2 (ja) | 2025-05-01 |
| US20240051987A1 (en) | 2024-02-15 |
| DK3864022T3 (da) | 2023-12-18 |
| WO2020077255A1 (en) | 2020-04-16 |
| EP4321519A3 (en) | 2024-05-01 |
| MX2024011494A (es) | 2024-09-26 |
| AU2025200422A1 (en) | 2025-02-13 |
| US11634453B2 (en) | 2023-04-25 |
| JP2024040444A (ja) | 2024-03-25 |
| US12686700B2 (en) | 2026-07-21 |
| AR116695A1 (es) | 2021-06-02 |
| AU2019357040B2 (en) | 2025-03-27 |
| TW202027753A (zh) | 2020-08-01 |
| EP3864022A1 (en) | 2021-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003166A1 (es) | Esteroides neuroactivos y composiciones de estos | |
| MX2024004790A (es) | Esteroides neuroactivos y sus metodos de uso. | |
| MX2021015848A (es) | Composiciones y métodos para el tratamiento de trastornos del snc. | |
| MX2020006608A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| BR112020012712A2 (pt) | composições e método para o tratamento de distúrbios do snc | |
| CO2022005128A2 (es) | Profármacos antivirales y formulaciones de los mismos | |
| MX2024011494A (es) | Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc. | |
| MA53858A (fr) | Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques | |
| PH12021550302A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| MX2025000126A (es) | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos | |
| ES2112880T3 (es) | Inhibidores de la proteasa de vih utiles para el tratamiento del sida. | |
| MX2016014921A (es) | Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas. | |
| MY154683A (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
| ZA201902051B (en) | Pharmaceutical composition | |
| MX2024014845A (es) | Esteroides neuroactivos no saturados 9(11) y sus metodos de uso | |
| AR112101A1 (es) | Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll). | |
| MX2021010022A (es) | Composicion farmaceutica. | |
| SV2018005733A (es) | Procedimientos para el tratamiento y la profilaxis de vih y sida | |
| MX2025010194A (es) | Formas cristalinas de estado solido de un modulador selectivo de canales de potasio | |
| ZA201902049B (en) | Pharmaceutical composition | |
| IL272562B1 (en) | Compounds or pharmaceutically acceptable salts thereof for the treatment of mycobacterial infection | |
| CO2022004768A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2023000680A1 (es) | Esteroides neuroactivos y composiciones de estos | |
| MX393833B (es) | Forma cristalina y sal de 3-(3,5-dicloro-4-hidroxibenzoil)-1,1-dioxo-2,3-dihidro-1,3-benzotiazol. | |
| WO2017143112A3 (en) | An oxazolidinone for treatment of infections with mycobacterium tuberculosis |